RecruitingEarly Phase 1NCT07538128

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

Studying Astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Huashan Hospital
Principal Investigator
Zhifeng Shi, Dr.
Huashan Hospital
Intervention
YSCH-01(biological)
Enrollment
10 target
Eligibility
18 years · All sexes
Timeline
20252027

Study locations (1)

Collaborators

Shanghai Yuansong Biotechnology Co., LTD

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07538128 on ClinicalTrials.gov

Other trials for Astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Astrocytoma

← Back to all trials